Open Innovation Drug Discovery

Compound Acquisition

To help us further explore new chemical space, the Lilly OIDD Program may invite select participants to have their compounds added to our collection for further screening, synthesis and other evaluation.


We select compounds based on an algorithm applied to the compound molecular descriptor profile. The molecular descriptor profile is derived from the secure structural information provided by the participating investigator. At no time during this process is the actual compound’s structure revealed to Lilly.

If Lilly has an interest in the molecule, the OIDD team will ask the participating investigator if he or she is interested in offering a sample for purchase. During this entire process, the compound structure itself remains confidential.